GAINESVILLE, Fla., Sept. 24, 2015 (GLOBE NEWSWIRE) -- AmnioLife Corporation, a human cells, tissues, and cellular and tissue-based products developer, today announced it has successfully completed sterilization validation testing using electron beam sterilization technology on its human demineralized bone matrix (DBM) allograft product line, Oncor™, for both U.S. and international commercialization. The Company expects to launch this product line during the fourth quarter of 2015 through its surgical distribution partners.
The Oncor™ DBM product line will be available for use in orthopedic applications such as spinal fusion, joint replacement, and trauma surgeries. The product family will consist of compressive strips, particulate, and flowable putty and moldable paste. The U.S. market for human DBM and other orthopedic biomaterials is expected to grow from $1.39B to $1.78B by 2020, or 66% market share in bone graft materials (http://healthcare.globaldata.com).
AmnioLife has successfully commercialized two other technologies it launched earlier in 2015: ProLifix™, an amniotic collagen matrix for surgical applications in various soft tissue surgeries, and Xceed™, a purified amniotic fluid product for use as a non-structural allograft used in joint and other musculoskeletal applications, for both in-office and in surgical applications.
About AmnioLife
AmnioLife is a research and development organization focused on placental-derived technologies and is building a GxP manufacturing program at its Gainesville, FL facility. The Company aims to commercialize a suite of minimally manipulated tissue products, global sales channel partners, and develop a strong IP-position for advanced biologic products. For more information, visit our website at http://www.amniolife.com.
Help employers find you! Check out all the jobs and post your resume.
The Oncor™ DBM product line will be available for use in orthopedic applications such as spinal fusion, joint replacement, and trauma surgeries. The product family will consist of compressive strips, particulate, and flowable putty and moldable paste. The U.S. market for human DBM and other orthopedic biomaterials is expected to grow from $1.39B to $1.78B by 2020, or 66% market share in bone graft materials (http://healthcare.globaldata.com).
AmnioLife has successfully commercialized two other technologies it launched earlier in 2015: ProLifix™, an amniotic collagen matrix for surgical applications in various soft tissue surgeries, and Xceed™, a purified amniotic fluid product for use as a non-structural allograft used in joint and other musculoskeletal applications, for both in-office and in surgical applications.
About AmnioLife
AmnioLife is a research and development organization focused on placental-derived technologies and is building a GxP manufacturing program at its Gainesville, FL facility. The Company aims to commercialize a suite of minimally manipulated tissue products, global sales channel partners, and develop a strong IP-position for advanced biologic products. For more information, visit our website at http://www.amniolife.com.
Help employers find you! Check out all the jobs and post your resume.